5 recruiting, 4 active not recruiting. 5 Phase 2, 3 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 3, Recruiting 2 |
| Phase 3 | 3 | Active not recruiting 2, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Metastatic Laryngeal Squamous Cell Carcinoma: new trials by email Literature Review of Metastatic Laryngeal Squamous Cell Carcinoma trials Research Report on Metastatic Laryngeal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation Audiometric Test, Interview - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Not applicable | Recruiting | Emory University | 118 | 2025-08-25 | 2026-07-16 |
| TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Emory University | 40 | 2025-05-08 | 2026-03-04 |
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment Biospecimen Collection, Cetuximab, Computed Tomography - Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 158 | 2025-03-27 | 2026-10-19 |
| Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial Biospecimen Collection, Computed Tomography, Lovastatin - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary | Phase 2 | Recruiting | Emory University | 28 | 2024-12-09 | 2026-02-11 |
| Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck Carboplatin, Cisplatin, Computed Tomography - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 290 | 2023-06-08 | 2026-09-14 |
| Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Atezolizumab, Bevacizumab, Biospecimen Collection - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 430 | 2023-03-13 | 2026-10-01 |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 150 | 2022-12-06 | 2026-10-20 |
| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Biopsy Procedure, Biospecimen Collection, Computed Tomography - Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 52 | 2022-07-26 | 2026-09-21 |
| Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Carboplatin, Cemiplimab, Paclitaxel - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Marcelo Bonomi | 46 | 2021-11-30 | 2026-06-25 |
Hypopharyngeal Neoplasms (9) · Laryngeal Neoplasms (9) · Mouth Neoplasms (9) · Squamous Cell Carcinoma of Head and Neck (9) · Carcinoma (8) · Oropharyngeal Neoplasms (7) · Nasopharyngeal Carcinoma (4) · Lymphoid Interstitial Pneumonia (1) · Melanoma (1) · Recurrence (1)
Carcinoma, Squamous Cell (9) · Head and Neck Neoplasms (9) · Laryngeal Diseases (9) · Mouth Diseases (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms by Site (9) · Neoplasms, Glandular and Epithelial (9) · Otorhinolaryngologic Diseases (9) · Otorhinolaryngologic Neoplasms (9) · Pharyngeal Diseases (9) · Pharyngeal Neoplasms (9) · Respiratory Tract Diseases (9) · Respiratory Tract Neoplasms (9) · Stomatognathic Diseases (9)
Magnetic Resonance Spectroscopy (6) · Specimen Handling (6) · pembrolizumab (5) · Carboplatin (3) · (225)Ac-DOTA-c(RGDyK) (2) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Biopsy (2) · Cetuximab (2) · Cisplatin (2) · Paclitaxel (2) · Platinum (2) · Taxes (2) · Bevacizumab (1) · Disulfides (1) · Docetaxel (1)
National Cancer Institute (NCI) (4) · Emory University (3) · ECOG-ACRIN Cancer Research Group (1) · Marcelo Bonomi (1)
United States (9)
Aarti Bhatia (1) · David J Sher (1) · Dong M. Shin, MD, FACP, FAAAS (1) · Jacob S Thomas (1) · Marcelo R Bonomi, MD (1) · Nicole C Schmitt, D, FACS (1) · Nicole C Schmitt, MD, FACS (1) · Siddharth Sheth (1) · Siwen Hu-Lieskovan (1)
P30CA138292 (3), U10CA180820 (2), K24DC022077 (1), R01CA262123 (1), U10CA180821 (1), U10CA180888 (1), UM1CA186717 (1)